Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Discovery of a new reprogramming mechanism for tumor cells

05.12.2011
Nature Medicine publishes a pioneering study about a protein that regulates the expression of hundreds of genes that have a crucial role in the progression of pancreatic cancer, gliomas and possibly many other kinds of tumor

A study by researchers Raúl Méndez, ICREA Research Professor at the Institute for Research in Biomedicine (IRB Barcelona) and Pilar Navarro at the IMIM (Institut de Recerca Hospital del Mar, Barcelona) describes a new reprogramming mechanism for the expression of genes responsible for turning a healthy cell into a tumor cell. In the study, published in this week's edition of Nature Medicine, the scientists have identified the protein CPEB4 as a "cellular orchestra conductor" that "activates" hundreds of genes associated with tumor growth.


The image shows the formation of new blood vessels in tumorous tissue do to the presence of CEPB-4. Credit: IRB Barcelona / IMIM

"The peculiarity is that it would not only be the mutation of a specific gene that promotes tumor growth but the expression of a protein in an incorrect site that "triggers" hundreds of messenger molecules (mRNAs), which transmit gene information for the synthesis of proteins, without these genes being mutated. This process leads to the expression of many "normal" genes but in unsuitable amounts and times that more greatly resemble early embryonic developmental stages rather than the stages of adult organ development", explains Raúl Méndez, an expert in the CPEB protein family. "This would be the case of tPA (tissue plasminogen activator), a protein that is not normally found in the healthy pancreas but that shows high expression in pancreatic tumors", clarifies Elena Ortiz-Zapater, the first author of the article, and Pilar Navarro.

Tumors are 80% smaller when CEPB4 is absent
One of the conclusions highlighted in the study is that in the tissues examined, pancreas and brain, CPEB4 is not detected in healthy cells but only in tumor ones. Thus inhibition of this protein would provide a highly specific anti-tumor treatment and with few adverse effects, "one of the main drawbacks of many cancer therapies", says Pilar Navarro, a researcher specialized in pancreatic cancer.

Using experiments involving human cancer cells in mice, these researchers have demonstrated that the decrease in CPEB4 levels in cancer cells reduces the size of tumors by up to 80%. Although the study is limited to two kinds of tumor, according to the co-authors, "given the effects observed in the tumors examined and the type of genes regulated by this mechanism, it is expected to be involved in many other types of cancer".

This study opens up avenues for new treatments for cancer, for which the researchers are designing and analyzing CPEB4 inhibitors of potential therapeutic interest. "The clinical applications are very promising, although intensive research is needed to identify inhibitory molecules and to test them in various models before determining their clinical potential and, in this case, their use in patients", warn Navarro and Méndez.

The study involved Francisco X. Real, at the Centro Nacional de Investigaciones Oncológicas (CNIO) and Eduardo Eyras, ICREA researcher, both from the Department of Experimental and Health Sciences at the Universitat Pompeu Fabra (UPF), together with Mar Iglesias and Francesc Alameda from the Pathology Service at Hospital del Mar.

Reference article:
Key contribution of CPEB4-mediated translational control to cancer progression.
Elena Ortiz-Zapater, David Pineda, Neus Martínez-Bosch, Gonzalo Fernández-Miranda, Mar Iglesias, Francesc Alameda, Mireia Moreno, Carolina Eliscovic, Eduardo Eyras, Francisco X. Real, Raúl Méndez and Pilar Navarro.

Nature Medicine (2011) doi:10.1038/nm.2540

Sonia Armengou | EurekAlert!
Further information:
http://www.irbbarcelona.org

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>